Yenos Analytical Unveils Revolutionary Urine Test for Early Cancer Detection

Yenos Analytical LLC has launched a pioneering urine test designed for early detection of multiple cancers, marking a significant advancement in cancer diagnostics. This innovative test known as the Yenos cancer test utilizes microRNA quantification and nanopore-array detection to provide high accuracy in identifying cancer signals from a simple urine sample. Unlike traditional methods that usually require blood draws, the Yenos test allows individuals to comfortably collect samples at home, making cancer screening more accessible than ever.

With a striking 97% sensitivity and specificity rate, the Yenos test is set to tackle an alarming gap in cancer screenings; approximately 90% of Americans have postponed health checkups, and cancers lacking recommended screenings make up 70% of annual cancer cases and deaths. This test targets stages I and II of common cancers including those of the prostate, pancreas, lung, breast, ovarian, and colorectal types, potentially allowing for earlier intervention and treatment. Dr. Anastassia Kanavarioti, Founder and CEO of Yenos Analytical, emphasizes this breakthrough, stating, "These exceptional results are attributed to using microRNA cancer biomarkers evaluated in hundreds of thousands of patients over the last 25 years. Our data suggests that the test can potentially identify nearly all cancers, even those like brain cancer which traditionally go undetected by DNA or protein biomarkers."

The Yenos test kit will be delivered to the customer's home via FedEx, complete with clear instructions on how to collect and send the urine sample back for analysis. This convenience extends to a nationwide audience, with FedEx handling both the shipment of the kit and the return of samples to the Yenos laboratory in California. Once processed, results are made available through a secure online portal, offering users easy access to their health information.

Recommended for adults aged 30-80 without a known cancer diagnosis in the past three years, the Yenos test is priced at $749 and may be eligible for health savings account use. Dr. Kanavarioti assures potential customers, "The Yenos cancer test provides peace of mind, whether that means being reassured of being cancer-free or recognizing the need for further medical consultation if cancer indicators are present. This simplifies the screening process significantly, allowing individuals to bypass the typical discomfort of blood draws."

As the only multi-cancer early detection (MCED) test that can utilize both blood and urine samples with equal efficiency, the Yenos cancer test represents a significant leap in diagnostics. The Yenos test is now available for order directly from Yenos Analytical's website, making advanced cancer detection accessible to a broader audience. This innovation not only highlights the importance of early detection in oncology but also promises to transform how individuals approach their health screenings in the future.

In summary, Yenos Analytical is disrupting cancer diagnostics with the launch of their unique urine test. By combining advanced scientific research with user-friendly technology, they are paving the way for more inclusive and effective cancer screening solutions.